Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 I124Rfs*6 RB1 del SMARCB1 loss |
Therapy | Tazemetostat |
Indication/Tumor Type | epithelioid sarcoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 I124Rfs*6 RB1 del SMARCB1 loss | epithelioid sarcoma | predicted - resistant | Tazemetostat | Case Reports/Case Series | Actionable | In a clinical case study, a patient with SMARCB1-deficient epithelioid sarcoma progressed on treatment with Tazverik (tazemetostat) and was found to have acquired a hemizygous deletion of RB1 and RB1 I124Rfs*6 (PMID: 38315003). | 38315003 |
PubMed Id | Reference Title | Details |
---|---|---|
(38315003) | Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. | Full reference... |